Drug intelligence / Profile preview

A-831

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

A-831 is an investigational small molecule drug developed by Arrow Therapeutics for the treatment of Hepatitis C. Clinical studies were conducted to evaluate its safety, tolerability, pharmacokinetic profile, and antiviral activity in male Hepatitis C carriers. Hepatitis C is caused by an RNA virus, and treatments often involve direct-acting antiviral agents.

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on A-831.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A-831.

Explore the full profile